宫颈细胞学阴性且高危型人乳头瘤病毒阳性人群的分流方法

doi:10.6040/j.issn.1671-7554.0.2016.644

摘要/Abstract

摘要： 目的分析宫颈细胞学阴性且高危型人乳头瘤病毒(HPV)阳性患者的宫颈活检病理结果,探讨Cervista HPV HR A9组病毒应用于此类人群分流的可行性。方法对1 376例于2011年1月至2016年1月健康查体的女性行新柏氏液基细胞学检测(TCT)和Cervista HPV HR检测,Cervista HPV HR检测结果分为A5/6、A7、A9组,将TCT阴性、HPV阳性患者转诊阴道镜检查,必要时行镜下宫颈活检术,分析A9组病毒感染与宫颈高级别上皮内瘤变CINII⁺(CINII及CINIII)的关系。结果 A5/6组、A7组及A9组阳性者分别占28.41%、21.51%、50.07%。A5/A6组、A7组及A9组中CINII⁺的发生率分别为1.28%、3.38%、15.82%,A9组中CINII⁺的发生率明显高于另外两组,其差异具有统计学意义(P<0.001, P<0.001)。A9组病毒感染者发生CINII⁺的风险是A5/A6组感染者的12.37倍,是A7组感染者的4.68倍。结论 Cervista HPV HR A9组病毒可用于TCT阴性、高危型HPV阳性者的分流。

关键词: 宫颈癌, 高危型人乳头瘤病毒, 宫颈细胞学, 宫颈上皮内瘤变

Abstract: Objective To analyze the cervical biopsy results in patients with negative cytological but positive high-risk HR-HPV test results, in order to explore the application of Cervista HPV HR A9 group virus in the identifying of such patients. Methods A total of 1,376 women who took physical examinations in our hospital during Jan. 2011 and Jan. 2016 received Cervista HR HPV test plus ThinPrep cytology(TCT). They were then divided into 3 groups according to the results of Cervista HR HPV test: A5/6, A7, and A9 groups. Those who had negative cytological but positive high-risk HPV test results underwent colposcopy or colposcopic biopsy if necessary. The correlation between A9 group virus infection and cervical high-grade intraepithelial neoplasia was analyzed. Results The positive rate in the A5/6, A7 and A9 group was respectively 28.41%, 21.51% and 28.41%. The incidence of CINII⁺ was 1.28%, 3.38% and 15.82%, respectively. The incidence of CINII⁺ in A9 group was obviously higher than that of the other two groups, and the difference was statistically significant(P<0.001, P<0.001). The risk of CINII⁺ in A9 group was 12.37 times of that in A5/A6 group and 4.68 times of that in A7 group. Conclusion Cervista HPV HR A9 group virus can be used to identify patients with negative cytological but positive high-risk HPV.

Key words: Human papilloma virus, Cervical cytological test, Cervical intraepithelial neoplasia, Cervical cancer

中图分类号:

R574

王雅芬,杨勇霞,刘娅,马德美,朱琳. 宫颈细胞学阴性且高危型人乳头瘤病毒阳性人群的分流方法[J]. 山东大学学报（医学版）, 2016, 54(8): 69-71.

WANG Yafen, YANG Yongxia, LIU Ya, MA Demei, ZHU Lin. Use of Cervista HPV HR A9 group virus to identify patients with negative cytological but positive high-risk HPV[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 69-71.

参考文献

[1] Castle PE, de Sanjosé S, Qiao YL, et al. Introduction of human papillomavirus DNA screening in the world: 15 years of experience[J]. Vaccine, 2012, 30 Suppl 5: F117-F122. doi: 10.1016/j.vaccine.2012.05.071.
[2] Zappacosta R, Caraceni D, Ciccocioppo L, et al. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme[J]. Gynecol Oncol, 2013, 128(3): 427-432.
[3] Sabatino SA, White MC, Thompson TD, et al. Cancer screening test use-United States, 2013[J]. MMWR Morb Mortal Wkly Rep, 2015, 64(17): 464-468.
[4] Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women[J]. Br J Cancer, 2001, 84(12): 1616-1623.
[5] Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections[J]. J Natl Cancer Inst, 2008, 100(7): 513-517.
[6] Stoler MH, Castle PE, Solomon D, et al. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays[J]. Am J Clin Pathol, 2007, 127(3): 335-337.
[7] Cervical cancer screening and prevention. Practice Bulletin No.157. American College of Obstetricians and Gynecologists[J]. Obstet Gynecol, 2016, 127(1): e1-e20.
[8] Day SP, Hudson A, Mast A, et al. Analytical performance of the investigational use only Cervista HPV HR test as determined by a multi-center study[J]. J Clin Virol, 2009, 45 Suppl 1: S63-S72. doi: 10.1016/S1386-6532(09)70010-1.
[9] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-386.
[10] Zhao J, Du H, Belinson JL, et al. Evaluation of the Cervista HPV A9 group in screening patients for cervical cancer[J]. J Med Screen, 2016, 23(1): 38-43.
[11] de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. Lancet Oncol, 2010, 11(11): 1048-1056.
[12] Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States[J]. J Natl Cancer Inst, 2009, 101(7): 475-487.
[13] Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis[J]. Lancet, 2005, 366(9490): 991-998.
[14] 李琳, 李坤. 女性生殖道人乳头瘤病毒多重感染基因谱的研究[J]. 现代妇产科进展, 2013, 22(7): 578-580.
[15] 梁凌云, 杜辉, 王纯, 等. 深圳人群人乳头瘤病毒感染亚型分布与宫颈上皮内瘤变现况横断面调查[J]. 北京大学学报(医学版), 2013, 45(1): 114-118. LIANG Lingyun, DU Hui, WANG Chun, et al. Crosssectional survey of human papilloma virus subtype distribution and cervical intraepithelial neoplasia in Shenzhen[J]. Journal of Peking University(Health Sciences), 2013, 45(1): 114-118.
[16] Liu XX, Fan XL, Yu YP, et al. Human papillomavirus prevalence and type-distribution among women in Zhejiang Province, southeast China: a cross-sectional study[J]. BMC Infect Dis, 2014, 14(1): 708.
[17] Ye J, Cheng X, Chen X, et al. Prevalence and risk profile of cervical human papillomavirus infection in Zhejiang Province, southeast China: a population-based study[J]. Virol J, 2010, 7: 66.
[18] Jing L, Zhong X, Zhong Z, et al. Prevalence of human papillomavirus infection in Guangdong Province, China: a population-based survey of 78,355 women[J]. Sex Transm Dis, 2014, 41(12): 732-738.
[19] Zhao J, Zhang X, Ma J, et al. Clinical performance characteristics of the Cervista HPV HR test kit in cervical cancer screening in China[J]. J Low Genit Tract Dis, 2012, 16(4): 358-363.

相关文章 15

[1]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[2]	任慧欣,郑茂金,韩文灿,王超群,周云,裴冬生. 过氧化氢通过调控自噬增强宫颈癌的放疗敏感性[J]. 山东大学学报 (医学版), 2023, 61(6): 22-28.
[3]	刘萌,侯丛哲,麻焕玉,张震,赵新蕊,张萍,朱琳. β-雌二醇对宫颈癌Hela细胞增殖的影响[J]. 山东大学学报 (医学版), 2023, 61(2): 9-15.
[4]	修德健,高正文,宋婷婷,崔楠,崔静,孙健平. 生物信息学方法分析与宫颈癌有关联的基因[J]. 山东大学学报 (医学版), 2022, 60(10): 99-109.
[5]	陈泉材,韩赛,刘露,孙雨,尤学武,张俊华,张友忠. CDC7、MCM4在105例宫颈病变组织中的表达及意义[J]. 山东大学学报 (医学版), 2022, 60(1): 34-39.
[6]	蔡春芳,易丹妮,郭芝亮,何耀娟. P16蛋白与TCT、HR-HPV的相关性及对不同子宫颈病变诊断的效能[J]. 山东大学学报 (医学版), 2022, 60(1): 40-47.
[7]	王璐,赵新蕊,朱琳. 25例早期宫颈癌无瘤化免举宫腹腔镜子宫切除术临床效果[J]. 山东大学学报 (医学版), 2021, 59(6): 76-80.
[8]	梁婷婷,杨勇霞,侯丛哲,黄太胜,王华丽,朱琳. PAX1基因甲基化与宫颈高级别上皮内病变及高危型HPV分型的关联性[J]. 山东大学学报 (医学版), 2021, 59(11): 48-52.
[9]	杨佳欣,沈铿,王遥. 妇科恶性肿瘤保留生育功能治疗的现状与展望[J]. 山东大学学报 (医学版), 2018, 56(5): 1-7.
[10]	陈颖,周小青,齐眉,张魏芳,刘娟,赵蔚明. 干扰PRPS2基因表达对宫颈癌细胞生物学特性的影响[J]. 山东大学学报 (医学版), 2018, 56(2): 9-13.
[11]	王永,姜晨,周士英,杨晓玫. IQ结构域GTP酶激活蛋白3表达对宫颈癌细胞增殖和转移的影响[J]. 山东大学学报 (医学版), 2018, 56(10): 103-109.
[12]	丁长宽,陈健行. 蛋白酶体抑制剂硼替佐米联合顺铂对宫颈癌细胞增殖的影响[J]. 山东大学学报 (医学版), 2018, 56(1): 70-75.
[13]	刘京康,杨建勇,孟丽华,姜洁. 血清miR-17-92簇在HPV阳性宫颈癌中的早期诊断价值[J]. 山东大学学报（医学版）, 2017, 55(5): 86-90.
[14]	孙泽雨,陈颖,林家香,刘娟,赵蔚明. 磷脂酰肌醇-4-磷酸酶II型对宫颈癌细胞增殖及凋亡的影响[J]. 山东大学学报（医学版）, 2017, 55(11): 1-6.
[15]	彭慧,何君梅,苏雪莲. 血清循环miR-375检测对宫颈癌早期诊断及术后监测的意义[J]. 山东大学学报（医学版）, 2016, 54(3): 68-71.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed